Skip to main content

Oxford Biomedica to host webinar showcasing the TetraVecta™ system

Written by Customer Service on . Posted in Public Companies.

Oxford Biomedica to host webinar showcasing the TetraVectaTM system

Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVectaTM system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023.

The webinar titled “4th Generation Lentiviral Vectors: An Improved Gene Delivery System” will feature presentations by Dr Nick Clarkson, Vice President, Head of Platform Research at Oxford Biomedica and Dr Dan Farley, Senior Director of the Vector Engineering Group at Oxford Biomedica, who will discuss how the TetraVecta™ system can significantly enhance the development and manufacturing of safer and more effective lentiviral vector-based therapies through improved quality, potency and packaging capacity. The presentation will also explore how these new vectors have the potential to streamline complex manufacturing processes, enhance productivity and open possibilities for developing new treatments.

The webinar will be held at 16:00 BST / 11:00 EST on Monday 2 October 2023, followed by a live Q&A session. To register for the webinar, please click here.

Oxford Biomedica’s TetraVectaTM system launched in May 2023 following years of development and on the basis of detailed understanding of specific industry challenges. This cutting-edge technology paves the way for genuine plug and play manufacturing and is being rolled out to support the development of more complex advanced therapies.

-Ends-

Enquiries:        

Oxford Biomedica plc:

Sebastien Ribault, Chief Commercial Officer – T: +44 (0)7519 109325 / E: partnering@oxb.com
Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 7394 562 425 / E: ir@oxb.com

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Davide Salvi

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn and YouTube.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.